Improving glycaemic control remains a key target to reduce complications in individuals with diabetes.1, –3 However, lowering glucose levels can be challenging, with less than 65% of individuals with type 2 diabetes reaching optimal HbA1c targets,4,5 decreasing further to 24% in those taking insulin.4 An important barrier for lowering glucose levels is the precipitation of hypoglycaemia, a potentially life-threatening complication of insulin therapy.1 The gene discussed is INS; the disease is type 2 diabetes mellitus.